Catalyst
Slingshot members are tracking this event:
Intellia Therapeutics (NTLA) set to commence non-human primate (NHP) studies on Transtherytin Amyloidosis (ATTR), a gene-editing therapy developed with Regeneron based on the CRISPR/Cas9 genetic editing system in 2017
- Source Link:
- http://seekingalpha.com/filing/3460363
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 01, 2018
Occurred Source:
http://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-first-quarter-2018-financial
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Non-human Primate, Crispr-cas9, Attr, Transtherytin Amyloidosis, Gene-editing
